This website uses cookies to help us give you the best experience when you visit our website. By continuing to use this website, you consent to our use of these cookies.

Find out more about how we use cookies and how to manage them by reading our cookie notice.

Lauren Drowley /Alleyn Plowright

Lauren Drowley, Associate Principal Scientist/Alleyn Plowright, Senior Principal Scientist

Lauren Drowley is an associate principal scientist and stem cell specialist at AstraZeneca in the Cardiovascular and Metabolic Disease area. Her current research is focused in cardiovascular regeneration where she is responsible for characterizing and developing relevant cell models and novel phenotypic assay development. In addition, she is involved in characterisation of adult and iPS-derived stem cell populations across species and understanding the biology in various drug projects, as well as in-house and external assessment of new potential drug targets. She received her PhD from University of Pittsburgh where she focused on stem cell transplantation for myocardial infarct repair, examining methods to improve efficacy. During her postdoctoral work at AstraZeneca, Dr. Drowley developed a high content imaging assay for brown fat differentiation from adipose stem cells and muscle progenitor cells for diabetes/obesity indications and examined the role of micro RNA in differentiation of muscle cells. She is also serving on the industrial committee for the International Society for Stem Cell Research.

Alleyn Plowright obtained his PhD in organic chemistry with Professor Gerald Pattenden at the University of Nottingham in 1999, and continued with postdoctoral studies with Professor Andrew Myers at Harvard University in 2000–2001. In 2002, he joined AstraZeneca UK as a medicinal chemist working in the Oncology and then Metabolic Disease research areas. He moved to AstraZeneca, Sweden, in 2006 and in 2012 became Senior Principal Scientist, Medicinal Chemistry in the Cardiovascular and Metabolic Diseases Innovative Medicines unit. His research interests include drug design, phenotypic screening and drug discovery for cardiovascular and metabolic diseases including regenerative medicine.

You are viewing: All posts Reset filters

Our Other Authors